C43 Stock Chart & Stats
€71.00
€2.60(3.80%)
At close: 4:00 PM EDT
€71.00
€2.60(3.80%)
Day’s Range― - ―
52-Week Range€57.50 - €141.00
Previous CloseN/A
Volume100.00
Average Volume (3M)48.00
Market Cap
€1.10B
Enterprise Value€963.95
Total Cash (Recent Filing)€195.28M
Total Debt (Recent Filing)€4.33M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,543,522
10 Day Avg. Volume20
30 Day Avg. Volume48
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€128.70Price Target Upside81.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.11
Revenue Forecast (FY)€114.24M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low debt ratios and substantial equity (~482M) provide durable financial flexibility. Over a 2–6 month horizon this conservatism supports continued R&D, potential milestone-funded programs, dividend continuity and the ability to absorb operational shocks without immediate external financing.
Proven High-margin PerformanceThe company demonstrated it can produce very high margins in favorable conditions, indicating strong product economics and pricing power. This historical capability implies that if revenues recover, operating leverage could rapidly restore profitability and cash generation over the medium term.
Diversified Revenue Model (sales + Licensing)A mixed model of direct product sales plus licensing and partner-funded development provides durable, non-dilutive funding sources. Milestones, royalties and partner commercialization reduce single-market exposure and can stabilize cash flows and support pipeline funding over several quarters.
Bears Say
Sharp Revenue Decline In 2025A >40% revenue drop materially weakens the business base and reduces operating leverage. Such a large structural decline compresses margins, complicates forecasting and may require cost restructuring or renewed partner efforts to restore sustainable top-line levels over the coming months.
Cash Generation Turned NegativeA swing from strong positive cash flow in 2024 to negative OCF and FCF strains internal funding for operations and development. Over a 2–6 month horizon this increases reliance on balance sheet buffers or partner financing and may force reprioritization of investments or dividend policy.
Inconsistent Profitability And ReturnsWide swings in ROE and repeated uneven earnings reduce visibility into sustainable earnings power. For stakeholders, inconsistent profitability complicates long-term planning, investor confidence and the ability to commit to multi-period investments or commercial expansion.
COSMO Pharmaceuticals N.V. News
C43 FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was €57.50 and its highest was €141.00 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is €1.10B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Mar 24, 2027 which is in 235 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2026. The company reported -€0.275 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.275.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. does not currently pay dividends.
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -€0.275 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went down -0.292%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in DE:C43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
C43 Stock 12 Month Forecast
Average Price Target
€128.70
▲(81.27% Upside)